Outcomes of Acute Myocardial Infarction in Patients with Familial Hypercholesteremia



      There is a paucity of contemporary data regarding the outcomes of acute myocardial infarction among patients with familial hypercholesteremia.


      We queried the Nationwide Readmissions Database (2016-2018) for hospitalizations with acute myocardial infarction. Multivariable regression analysis was used to compare in-hospital outcomes and 30-day readmissions among patients with and without familial hypercholesteremia.


      The analysis included 1,363,488 hospitalizations with acute myocardial infarction. The prevalence of familial hypercholesteremia was 0.07% among acute myocardial infarction admissions. Compared with those without familial hypercholesteremia, admissions with familial hypercholesteremia were younger and had less comorbidities but were more likely to have had prior infarct and revascularization. Admissions with familial hypercholesteremia were more likely to present with ST-elevation myocardial infarction and undergo revascularization. After multivariable adjustment, there was no difference in in-hospital case fatality among patients with hypercholesteremia compared with those without it (adjusted odds ratio [aOR] = 0.76; 95% confidence interval [CI] 0.41-1.39). Admissions with acute myocardial infarction and familial hypercholesteremia had higher adjusted rates of cardiac arrest and utilization of mechanical support. There were no group differences in overall 30-day readmission (aOR 0.75; 95% CI 0.51-1.10) or 30-day readmission for acute myocardial infarction. However, a nonsignificant trend toward higher readmission for percutaneous coronary intervention was observed among patients with familial hypercholesteremia (aOR 1.89; 95% CI 0.98-3.64).


      In this contemporary nationwide observational analysis, patients with familial hypercholesteremia represent a small proportion of the overall population with acute myocardial infarction and have a distinctive clinical profile but do not appear to have worse in-hospital case fatality compared with those without familial hypercholesteremia.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Nanchen D
        • Gencer B
        • Muller O
        • et al.
        Prognosis of patients with familial hypercholesterolemia after acute coronary syndromes.
        Circulation. 2016; 134: 698-709
        • Hobbs HH
        • Brown MS
        • Goldstein JL
        Molecular genetics of the LDL receptor gene in familial hypercholesterolemia.
        Hum Mutat. 1992; 1: 445-466
        • Wiesbauer F
        • Blessberger H
        • Azar D
        • et al.
        Familial-combined hyperlipidaemia in very young myocardial infarction survivors (≤ 40 years of age).
        Eur Heart J. 2009; 30: 1073-1079
        • Wang X
        • Cai G
        • Wang Y
        • et al.
        Comparison of long-term outcomes of young patients after a coronary event associated with familial hypercholesterolemia.
        Lipids Health Dis. 2019; 18: 131
        • Zafrir B
        • Jubran A
        • Lavie G
        • Halon DA
        • Flugelman MY
        • Shapira C
        Clinical features and gaps in the management of probable familial hypercholesterolemia and cardiovascular disease.
        Circ J. 2017; 82: 218-223
        • Tada H
        • Kawashiri M-a
        • Okada H
        • et al.
        Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography.
        Am J Cardiol. 2015; 115: 724-729
        • Danchin N
        • Farnier M
        • Zeller M
        • et al.
        Long-term outcomes after acute myocardial infarction in patients with familial hypercholesterolemia. The FAST-MI programme.
        J Clin Lipidol. 2020; 14: 352-360.e6
        • Al-Rasadi K
        • Al-Zakwani I
        • Alsheikh-Ali AA
        • et al.
        Prevalence, management, and outcomes of familial hypercholesterolemia in patients with acute coronary syndromes in the Arabian Gulf.
        J Clin Lipidol. 2018; 12: 685-692.e682
        • Agency for Healthcare Research and Quality
        Healthcare Cost and Utilization Project, NRD Database Documentation.
        Agency for Healthcare Research and Quality, Rockville, MD2019
        • Altibi AM
        • Prousi G
        • Agarwal M
        • et al.
        Readmission-free period and in-hospital mortality at the time of first readmission in acute heart failure patients—NRD-based analysis of 40,000 heart failure readmissions.
        Heart Fail Rev. 2021; 26: 57-64
        • Elbadawi A
        • Elgendy IY
        • Lee B
        • et al.
        Transcatheter edge-to-edge repair with mitraclip in systolic heart failure with ischemic versus nonischemic cardiomyopathy.
        JACC Cardiovasc Interv. 2020; 13: 2818-2819
        • Safarova MS
        • Liu H
        • Kullo IJ
        Rapid identification of familial hypercholesterolemia from electronic health records: the SEARCH study.
        J Clin Lipidol. 2016; 10: 1230-1239
        • Mues KE
        • Bogdanov AN
        • Monda KL
        • Yedigarova L
        • Liede A
        • Kallenbach L
        How well can familial hypercholesterolemia be identified in an electronic health record database?.
        Clin Epidemiol. 2018; 10: 1667
        • Brennan JM
        • Curtis JP
        • Dai D
        • et al.
        Enhanced mortality risk prediction with a focus on high-risk percutaneous coronary intervention: results from 1,208,137 procedures in the NCDR (National Cardiovascular Data Registry).
        JACC Cardiovasc Interv. 2013; 6: 790-799
        • Ellis KL
        • Pang J
        • Watts GF
        Registries, codifications and cardiovascular outcomes in familial hypercholesterolaemia.
        SAGE Publications, London, UK2017
        • Mundal L
        • Igland J
        • Ose L
        • et al.
        Cardiovascular disease mortality in patients with genetically verified familial hypercholesterolemia in Norway during 1992–2013.
        Eur J Preven Cardiol. 2017; 24: 137-144
        • Hu P
        • Dharmayat KI
        • Stevens CA
        • et al.
        Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis.
        Circulation. 2020; 141: 1742-1759
        • Rerup SA
        • Bang LE
        • Mogensen UM
        • et al.
        The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction.
        Am Heart J. 2016; 181: 35-42
        • Khera AV
        • Won H-H
        • Peloso GM
        • et al.
        Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia.
        J Am Coll Cardiol. 2016; 67: 2578-2589
        • Austin MA
        • Hutter CM
        • Zimmern RL
        • Humphries SE
        Familial hypercholesterolemia and coronary heart disease: a HuGE association review.
        Am J Epidemiol. 2004; 160: 421-429
        • Stone NJ
        • Levy RI
        • Fredrickson DS
        • Verter J
        Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia.
        Circulation. 1974; 49: 476-488
        • Björck L
        • Wallentin L
        • Stenestrand U
        • Lappas G
        • Rosengren A
        Medication in relation to ST-segment elevation myocardial infarction in patients with a first myocardial infarction: Swedish Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA).
        Arch Intern Med. 2010; 170: 1375-1381
        • Sugiyama T
        • Hasegawa K
        • Kobayashi Y
        • Takahashi O
        • Fukui T
        • Tsugawa Y
        Differential time trends of outcomes and costs of care for acute myocardial infarction hospitalizations by ST elevation and type of intervention in the United States, 2001–2011.
        J Am Heart Assoc. 2015; 4e001445
        • Arnold SV
        • Magnuson EA
        • Wang K
        • et al.
        Do differences in repeat revascularization explain the antianginal benefits of bypass surgery versus percutaneous coronary intervention? Implications for future treatment comparisons.
        Circ Cardiovasc Qual Outcomes. 2012; 5: 267-275
        • US Department of Health and Human Services
        2015 National Healthcare Quality and Disparities Report and 5th Anniversary Update on the National Quality Strategy.
        Agency for Healthcare Research and Quality, Rockville, MD2016
        • Agency for Healthcare Research and Quality
        HCUP Quality Control Procedures.
        Agency for Healthcare Research and Quality, Rockville, MD2019